Novo Nordisk and Eli Lilly Battle for a Slice of India’s Obesity Market | Vantage with Palki Sharma

00:05:16
https://www.youtube.com/watch?v=euj6I_KD1kA

Résumé

TLDRThis video explores the pivotal role of weight loss drugs in 2024, particularly focusing on the Indian market. Novo Nordisk's obesity drugs, OIC and Wegovy, have become globally popular, contributing to the company's status as Europe's most valuable. However, these drugs are yet to launch in India. Competition from Eli Lilly, which has received drug approvals in India, pressures Novo Nordisk to expedite its launch. With 80 million obese and 225 million overweight people, India's market potential is immense. While demand grows, the drugs are costly, with prices over $1,000 monthly, making them inaccessible to many. The upcoming patent expiration in 2026 could allow Indian firms to produce generics, potentially lowering costs. The scenario underscores India's dual challenge of obesity and malnutrition, reflecting significant health inequalities.

A retenir

  • ⚖️ India's market for weight loss drugs is becoming increasingly significant due to high obesity rates.
  • 💊 Novo Nordisk and Eli Lilly are competing to capture the Indian market with their weight loss drugs.
  • 🗓️ Novo Nordisk aims to advance the launch of its drugs in India to counter Eli Lilly's competition.
  • 📈 India's weight management market is projected to grow to $336 million by 2028.
  • 💰 The high cost of weight loss drugs makes them unaffordable for most Indians.
  • 🧪 Indian pharmaceutical companies are developing alternatives to high-priced foreign drugs.
  • 📉 Patent expiration in 2026 may lead to more affordable generic versions of weight loss drugs.
  • 🌍 India's health market reflects stark inequalities with obesity and malnutrition both prevalent.
  • 🚨 The increasing demand for weight loss drugs highlights a growing global trend.
  • 🔍 Novo Nordisk is already Europe's most valuable company because of its obesity drugs.

Chronologie

  • 00:00:00 - 00:05:16

    In the last month of 2024, weight loss drugs have become mainstream globally, except in India. Novo Nordisk, a leading Danish drug maker known for obesity drugs like Wegovy and Ozempic, plans to launch these drugs earlier in India, fearing competition from American giant Eli Lilly. Eli Lilly's drugs have regulatory approval for diabetes in India, with weight loss approval likely by early 2025. Novo Nordisk worries about losing its foothold in India's potential market where 80 million people are obese. India's weight management market is expected to double by 2028, leading to demand for legally approved weight loss drugs. Due to current unavailability, Indians are paying extra to import these drugs.

Carte mentale

Vidéo Q&R

  • What are some weight loss drugs mentioned?

    OIC, Wegovy, Mounjaro, and Zybault are mentioned.

  • Which company is Europe's most valuable due to these drugs?

    Novo Nordisk is Europe's most valuable company due to its obesity drugs.

  • Why does Novo Nordisk want to launch its drugs early in India?

    They want to counter competition from Eli Lilly, which has received approval for other medications.

  • When are Novo Nordisk's patents on semaglutide expected to expire in India?

    They are expected to expire in 2026.

  • What is the projected market size of India's weight management industry by 2028?

    It is projected to be worth $336 million by 2028.

  • How much do weight loss drugs like OIC and Wegovy cost?

    OIC costs around $1,000 per month, and Wegovy costs around $1,300 per month.

  • What challenges do weight loss drugs face in India?

    The price is unaffordable for most, and there are legal hurdles. Smuggling and counterfeit issues also exist.

  • What factors make India a major market for weight loss drugs?

    India has a high obesity rate with 80 million obese and 225 million overweight individuals.

  • Are Indian pharmaceutical companies planning to enter the weight loss market?

    Yes, companies like Sun Pharma and Cipla are developing new drugs.

  • What societal issue does this weight loss drug trend highlight in India?

    It highlights stark inequalities, with both high obesity and malnutrition rates present.

Voir plus de résumés vidéo

Accédez instantanément à des résumés vidéo gratuits sur YouTube grâce à l'IA !
Sous-titres
en
Défilement automatique:
  • 00:00:04
    we're in the last month of 2024 a lot of
  • 00:00:06
    things have defined this year elections
  • 00:00:08
    Wars artificial intelligence once what
  • 00:00:11
    such phenomenon is weight loss drugs
  • 00:00:13
    especially the likes of
  • 00:00:15
    OIC the world got a peak of them in 2022
  • 00:00:20
    they triggered a storm in 2023 and this
  • 00:00:23
    year they became the new normal not in
  • 00:00:25
    India though but that could change very
  • 00:00:27
    soon reports suggest that no no Nordisk
  • 00:00:30
    is pushing for an early launch in
  • 00:00:33
    India some background here NOA Nordisk
  • 00:00:36
    is a Danish drug maker it makes two
  • 00:00:38
    obesity drugs OIC and vovi there are a
  • 00:00:42
    rage across the globe and that's
  • 00:00:45
    propelled the rise of NOA Nordisk the
  • 00:00:47
    demand was so high that they struggled
  • 00:00:49
    with the Supply right now it's Europe's
  • 00:00:52
    Most Valuable company however both these
  • 00:00:54
    drugs OIC and vovi are not available in
  • 00:00:58
    India the plan was to release them in
  • 00:01:01
    2026 but now Nova nisk wants to do it
  • 00:01:04
    earlier sometime next year else they're
  • 00:01:07
    worried that they will lose India as a
  • 00:01:08
    market and that's because of another
  • 00:01:10
    company Ellie Lily it's an American
  • 00:01:13
    pharmaceutical giant Ellie ly also has
  • 00:01:15
    two weight loss drugs monaru and and Zeb
  • 00:01:18
    Bound in July this year they got a green
  • 00:01:21
    light from India's drug regulator the
  • 00:01:23
    approval was for type two diabetes for
  • 00:01:26
    these drugs to be used for type two
  • 00:01:27
    diabetes not weight loss but weight loss
  • 00:01:30
    is also under review and Ellie Lily is
  • 00:01:32
    said to be pushing for it the approval
  • 00:01:34
    could come in early 2025 so in the next
  • 00:01:37
    few months and this has left Novo
  • 00:01:39
    Nordisk spooked they fear that they
  • 00:01:42
    could lose India to Ellie Lily hence the
  • 00:01:44
    rush to launch a new report suggests
  • 00:01:47
    that Novo Nordisk even has regulatory
  • 00:01:49
    approvals they apparently got them from
  • 00:01:51
    India in
  • 00:01:53
    2022 although there's no official
  • 00:01:55
    confirmation on
  • 00:01:57
    this but for a moment let's take a step
  • 00:01:59
    back can look at the bigger picture why
  • 00:02:01
    are these companies battling over
  • 00:02:04
    India because of the numbers the size of
  • 00:02:07
    the market in India 80 million people
  • 00:02:10
    are obese 80 80 million people are obese
  • 00:02:13
    and another 225 million people are
  • 00:02:15
    overweight when it comes to Global
  • 00:02:18
    obesity rankings India stands third
  • 00:02:20
    right behind the US and China by 2034
  • 00:02:24
    11% of our population will be obese and
  • 00:02:27
    that makes India a major market for
  • 00:02:29
    weight loss drugs going forward and the
  • 00:02:31
    demand is already soaring in 2022
  • 00:02:34
    India's weight management Market was
  • 00:02:36
    worth around 180 million by 2028 it is
  • 00:02:40
    projected to be worth $336 million
  • 00:02:43
    weight loss drugs are not legally
  • 00:02:45
    available here yet but thousands of
  • 00:02:47
    people are already buying and using them
  • 00:02:50
    they either smuggle them from abroad or
  • 00:02:52
    buy counterfeit versions online or
  • 00:02:54
    import them from
  • 00:02:55
    Europe so these Indians are basically
  • 00:02:57
    paying extra for Cal storage plus sh
  • 00:02:59
    shipping plus customs and tax just to
  • 00:03:02
    get their hands on weight loss drugs
  • 00:03:04
    which are already quite expensive to
  • 00:03:06
    start with OIC for instance will cost
  • 00:03:09
    you around $1,000 a month that's more
  • 00:03:11
    than 80,000 Indian rupees every
  • 00:03:14
    month we go we cost around $1,300 per
  • 00:03:17
    month that's over 1 lakh Rupees at that
  • 00:03:21
    price point it's unaffordable for most
  • 00:03:23
    people in
  • 00:03:24
    India so what's the solution well there
  • 00:03:27
    are two ways around it first Indian
  • 00:03:29
    farmer Jam s entering the market which
  • 00:03:31
    is already happening the likes of
  • 00:03:32
    sunfarm and cipla they're working on new
  • 00:03:34
    drugs the tests have been positive
  • 00:03:36
    they're expected to be released soon the
  • 00:03:38
    second way around this is patent expiry
  • 00:03:42
    you see Nova Nordisk drugs contain an
  • 00:03:44
    active ingredient called
  • 00:03:47
    semaglutide semaglutide is what causes
  • 00:03:50
    the weight loss the company has a patent
  • 00:03:53
    for semaglutide which means that no one
  • 00:03:56
    else can make a similar drug legally but
  • 00:03:59
    that patent expires in India in 2026 so
  • 00:04:01
    after that after 2026 Indian Pharma
  • 00:04:04
    companies can make generic versions of
  • 00:04:06
    this
  • 00:04:07
    drug and that could drive down the price
  • 00:04:10
    going forward expect all of this to
  • 00:04:12
    happen the entry of foreign players the
  • 00:04:14
    launch of local Brands and the creation
  • 00:04:16
    of generic
  • 00:04:18
    versions and it is quite interesting
  • 00:04:20
    that all of this is playing out here in
  • 00:04:22
    India because this is a unique case yes
  • 00:04:25
    India is high up on the Obesity scale
  • 00:04:27
    but it also has a significant Mal
  • 00:04:29
    nutrition problem more than 800 million
  • 00:04:32
    people in India depend on food subsidies
  • 00:04:34
    an even bigger number gets insufficient
  • 00:04:37
    nutrition so while one part of the
  • 00:04:39
    population struggles with excess another
  • 00:04:42
    struggles with
  • 00:04:44
    access it's a reminder of the Stark
  • 00:04:47
    inequalities and of the gaps that need
  • 00:04:49
    to be bridged so that we head into a
  • 00:04:51
    future where health is not a luxury but
  • 00:04:54
    a universal
  • 00:04:58
    right for
Tags
  • Weight Loss Drugs
  • Novo Nordisk
  • Eli Lilly
  • OIC
  • Wegovy
  • Semaglutide
  • India Market
  • Obesity
  • Pharmaceutical Industry
  • Health Inequality